These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22550979)

  • 21. Long term retention of retigabine in a cohort of people with drug resistant epilepsy.
    Wehner T; Chinnasami S; Novy J; Bell GS; Duncan JS; Sander JW
    Seizure; 2014 Nov; 23(10):878-81. PubMed ID: 25175006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison.
    Martyn-St James M; Glanville J; McCool R; Duffy S; Cooper J; Hugel P; Lane PW
    Seizure; 2012 Nov; 21(9):665-78. PubMed ID: 22902288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
    Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
    Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
    Faulkner MA; Burke RA
    Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.
    Craig D; Rice S; Paton F; Fox D; Woolacott N
    Pharmacoeconomics; 2013 Feb; 31(2):101-10. PubMed ID: 23341194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.
    Gil-Nagel A; Brodie MJ; Leroy R; Cyr T; Hall S; Castiglia M; Twomey C; VanLandingham K
    Epilepsy Res; 2012 Nov; 102(1-2):117-21. PubMed ID: 22771137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
    Deeks ED
    CNS Drugs; 2011 Oct; 25(10):887-900. PubMed ID: 21936589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.
    Brodie MJ; French JA; McDonald SA; Lee WJ; Adams B; Scott A; Nohria V; DeRossett S
    Epilepsy Res; 2014 Jul; 108(5):989-94. PubMed ID: 24726452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ezogabine treatment of childhood absence epilepsy.
    Vossler DG; Yilmaz U
    Epileptic Disord; 2014 Mar; 16(1):121-4. PubMed ID: 24659629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retigabine: fewer drug interactions.
    Prescrire Int; 2012 Mar; 21(125):61. PubMed ID: 22428181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retigabine as add-on treatment of refractory epilepsy--a cost-utility study in a Swedish setting.
    Kristian B; Wachtmeister K; Stefan F; Forsgren L
    Acta Neurol Scand; 2013 Jun; 127(6):419-26. PubMed ID: 23368976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
    Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
    J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comment on Craig et al.: ''Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization: a NICE single technology appraisal''.
    Holko P; Kawalec P
    Pharmacoeconomics; 2013 Jun; 31(6):533-5. PubMed ID: 23539279
    [No Abstract]   [Full Text] [Related]  

  • 34. The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model.
    Bloms-Funke P; Bankstahl M; Bankstahl J; Kneip C; Schröder W; Löscher W
    Neuropharmacology; 2022 Feb; 203():108884. PubMed ID: 34785163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lacosamide for the treatment of epilepsy.
    Krauss GL; Edwards HB; Lin B
    Ann Med; 2012 Nov; 44(7):674-9. PubMed ID: 22380697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures.
    Amabile CM; Vasudevan A
    Pharmacotherapy; 2013 Feb; 33(2):187-94. PubMed ID: 23386597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
    Patsalos PN; Berry DJ
    Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ezogabine (Potiga) for epilepsy.
    Med Lett Drugs Ther; 2012 Aug; 54(1397):65-7. PubMed ID: 22907178
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures.
    Faught E; Holmes GL; Rosenfeld WE; Novak G; Neto W; Greenspan A; Schmitt J; Yuen E; Reines S; Haas M
    Neurology; 2008 Nov; 71(20):1586-93. PubMed ID: 19001248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
    Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
    PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.